Back

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

26 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Cardiovascular risk and its modification Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

5 More presentations in this session

Presentation thumbnail
Miss M. Schreuder (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Professor P. Meikle (Melbourne, AU)
Abstract Slides
Presentation thumbnail
Professor G. De Ferrari (Turin, IT)
Abstract Slides
Presentation thumbnail
Professor S. Bain (Swansea, GB)
Abstract Slides
Presentation thumbnail
Doctor D. Fitchett (Toronto, CA)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Cardiovascular risk and its modification

The Event

Event poster

ESC Congress 2018

26 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources